BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10067701)

  • 1. Intranasal or subcutaneous co-administration of recombinant cholera toxin B subunit stimulates only a slight or no level of the specific IgE response in mice to tetanus toxoid.
    Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Miura Y; Matano K; Goto N; Tochikubo K
    Vaccine; 1999 Feb; 17(7-8):944-8. PubMed ID: 10067701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit.
    Isaka M; Yasuda Y; Kozuka S; Miura Y; Taniguchi T; Matano K; Goto N; Tochikubo K
    Vaccine; 1998 Oct; 16(17):1620-6. PubMed ID: 9713937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies.
    Yasuda Y; Isaka M; Taniguchi T; Zhao Y; Matano K; Matsui H; Morokuma K; Maeyama J; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Jun; 21(21-22):2954-63. PubMed ID: 12798639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Matano K; Maeyama J; Komiya T; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 1999 Nov; 18(7-8):743-51. PubMed ID: 10547435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Mizokami M; Kozuka S; Taniguchi T; Matano K; Maeyama J; Mizuno K; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2001 Jan; 19(11-12):1460-6. PubMed ID: 11163669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
    Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine.
    Isaka M; Komiya T; Takahashi M; Yasuda Y; Taniguchi T; Zhao Y; Matano K; Matsui H; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2004 Aug; 22(23-24):3061-8. PubMed ID: 15297056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates.
    Johansson EL; Rask C; Fredriksson M; Eriksson K; Czerkinsky C; Holmgren J
    Infect Immun; 1998 Feb; 66(2):514-20. PubMed ID: 9453604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal sensitization with Blomia tropicalis antigens induces allergic responses in mice characterized by elevated antigen-specific and non-specific serum IgE and peripheral blood eosinophil counts.
    Takeda F; Arakawa T; Toma H; Ishii A; Sato Y
    Rev Inst Med Trop Sao Paulo; 2004; 46(1):1-8. PubMed ID: 15057325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral vaccination against Helicobacter pylori with recombinant cholera toxin B-subunit.
    Kubota E; Joh T; Tanida S; Sasaki M; Kataoka H; Watanabe K; Itoh K; Oshima T; Ogasawara N; Togawa S; Wada T; Yamada T; Mori Y; Fujita F; Shimura T; Ohara H; Isaka M; Yasuda Y; Itoh M
    Helicobacter; 2005 Aug; 10(4):345-52. PubMed ID: 16104951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues.
    van Ginkel FW; Jackson RJ; Yuki Y; McGhee JR
    J Immunol; 2000 Nov; 165(9):4778-82. PubMed ID: 11045998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.
    Roberts M; Bacon A; Rappuoli R; Pizza M; Cropley I; Douce G; Dougan G; Marinaro M; McGhee J; Chatfield S
    Infect Immun; 1995 Jun; 63(6):2100-8. PubMed ID: 7768587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines.
    Mark A; Björkstén B; Granström M
    Vaccine; 1995 May; 13(7):669-73. PubMed ID: 7668036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin.
    Tamura S; Shoji Y; Hasiguchi K; Aizawa C; Kurata T
    Vaccine; 1994 Oct; 12(13):1238-40. PubMed ID: 7839730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
    Kundu J; Mazumder R; Srivastava R; Srivastava BS
    FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin.
    Marinaro M; Boyaka PN; Jackson RJ; Finkelman FD; Kiyono H; Jirillo E; McGhee JR
    J Immunol; 1999 Jan; 162(1):114-21. PubMed ID: 9886376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with recombinant Streptococcus gordonii expressing tetanus toxin fragment C confers protection from lethal challenge in mice.
    Medaglini D; Ciabattini A; Spinosa MR; Maggi T; Marcotte H; Oggioni MR; Pozzi G
    Vaccine; 2001 Feb; 19(15-16):1931-9. PubMed ID: 11228363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
    Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
    Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.